Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Tina Nova, Mark Guyer

Premium

Illumina has hired Tina Nova to be senior vice president and general manager of the firm's oncology business. Rick Klausner has been serving as interim oncology leader since January and will continue in his role as senior vice president and chief medical officer.

Nova is cofounder of molecular diagnostic company Genoptix and served as its president and CEO from 2000. She also cofounded Nanogen, a provider of MDx tests, and served as its COO and president from 1994 until 2000. She holds a BS in biological sciences from the University of California, Irvine and a PhD in biochemistry from the University of California, Riverside.


Mark Guyer has retired from his post as deputy director of the National Human Genome Research Institute.

Guyer has worn many hats at NHGRI since he joined the Office of Human Genome Research, the institute's precursor, in 1998, and he helped guide NHGRI's research activities from the earliest days of the Human Genome Project. He contributed to "making the various parts of the HGP come together as a working project," NHGRI said, and helped NHGRI come together as an organization. Although he was not the architect of the HGP, he played an "indispensable" role in so many aspects of the project, NIH Director Francis Collins said.

In 2002, Guyer became director of the NHGRI Division of Extramural Research, now the Extramural Research Program, and he has had a hand in establishing programs such as the 1,000 Genomes Project; the Large-Scale Genome Sequencing and Analysis Centers; the Ethical, Legal and Social Implications research program; and The Cancer Genome Atlas project, among others.

Although he officially retired on June 30, Guyer will continue to work at NHGRI on a part-time basis on the H3Africa Program and the Big Data to Knowledge initiative.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.